Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Celiac Disease Clinical Trial

Official title:

A Multicentre, SAD, and MAD Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IV Treatment of CALY-002 in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04593251
• Other study ID #: CALY-CL19-001
• Status: Completed
• Phase: Phase 1
• Start date: September 28, 2020
• Est. completion date: April 2, 2024

Study information

• Verified date: April 2024
• Source: Calypso Biotech BV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single and multiple ascending study to characterize the safety, PK, PD and clinical effect in healthy volunteers and participants with Celiac Disease and Eosinophilic Esophagitis.

Description:

This is a multi-site, randomized, placebo controlled single and multiple dose escalation study of an anti-IL-15 mAb (CALY-002). The study initiates as placebo controlled, randomized trial with a single ascending dosing part in healthy subjects and commences with a multiple ascending dosing part in participants with Celiac Disease undergoing a gluten challenge and includes open label multiple dose expansion cohorts in participants with Eosinophilic Esophagitis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: April 2, 2024
• Est. primary completion date: April 2, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Part A. Healthy Subjects:

1. Male or female aged between 18 and 50 years (both inclusive)

2. Must be healthy on the basis of the physical examination findings, clinical laboratory tests, medical history, vital signs, and cardiac monitoring (normal 12 lead electrocardiogram [ECG] results) performed at screening, in the opinion of the investigator

• Part B. Subjects with Celiac Disease (CeD):

1. Male or female = 18 years of age.

2. Diagnosis of CeD by intestinal biopsy at least 12 months prior to screening as confirmed by medical records.

3. No histological signs of active CeD at screening

4. Gluten-free diet (GFD) for at least 12 consecutive months prior to screening

5. Willing to undertake a gluten challenge (intake of approximately 3 g of gluten daily) for 56 consecutive days

6. Must be healthy on the basis of physical examination findings, clinical laboratory tests, medical history, vital signs, and cardiac monitoring (normal 12 lead ECG results) performed at screening, in the opinion of the investigator.

• Part C. Subjects with Eosinophilic Esophagitis (EoE):

1. Male or female = 18 years of age.

2. Must have endoscopically confirmed and documented diagnosis of EoE

3. Should exhibit active symptoms of dysphagia with more than 3 episodes of dysphagia during a period of 2 weeks during screening.

4. Must have clinically active disease

5. Must have had a relapsed EoE or did not respond after first line therapy

6. Subject must be healthy on the basis of physical examination findings, clinical laboratory tests, medical history, vital signs, and cardiac monitoring (normal 12 lead ECG results) performed at screening, in the opinion of the investigator.

Exclusion Criteria:

• Part A. Healthy Subjects excluded:

1. Any significant medical condition, laboratory abnormality, or psychiatric illness

2. Any condition that confounds the ability to interpret data from the study.

3. Currently receiving or has been previously treated with a biologic agent.

4. History of anaphylactic reactions to protein therapeutics.

5. Has current or recent (within 4 weeks prior to screening) signs or symptoms of infection that require parenteral antibiotic administration.

6. Has evidence of SARS-CoV-2 infection and/or subject Is deemed at risk for the coronavirus disease (COVID-19)

7. Has had major surgery (including joint surgery) within 8 weeks prior to screening and hospitalisation for a clinically relevant event within the 4 weeks prior to screening.

• Part B. Subjects with Celiac Disease (CeD) excluded:

1. A concurrent active autoimmune disease (other than CeD) that requires systematic treatment with immunosuppressants.

2. Has severe complication of CeD such as refractory CeD.

3. Has active (microscopic) colitis with clinical signs of diarrhoea and abdominal pain.

4. Is currently receiving or has been previously treated with a biologic agent.

5. Has a history of anaphylactic reactions to protein therapeutics.

6. Subject has evidence of SARS-CoV-2 infection and/or subject is deemed at risk for the coronavirus disease (COVID-19).

• Part C: Subjects with Eosinophilic Esophagitis (EoE) excluded:

1. Has a hyper-eosinophilic syndrome.

2. Has a concurrent active autoimmune disease (other than EoE) that requires treatment with immunosuppressants.

3. Has active (microscopic) colitis with clinical signs of diarrhoea and abdominal pain.

4. Currently receiving or has been previously treated with a biologic agent.

5. Has a history of anaphylactic reactions to protein therapeutics.

6. Subject has evidence of SARS-CoV-2 infection and/or subject is deemed at risk for the coronavirus disease (COVID-19).

Related Conditions & MeSH terms

• Celiac Disease
• Eosinophilic Esophagitis
• Esophagitis

Intervention

Biological:
• CALY-002
1-hour intravenous infusion
• Placebo
1-hour intravenous infusion

Locations

Country	Name	City	State
Belgium	Cliniques Universitaires Saint-Luc - Hospital	Brussel
Belgium	UZ Leuven	Leuven
Finland	Tampere University Hospital	Tampere
Germany	Charite	Berlin
Germany	Universitatsklinikum Erlangen - Hospital	Erlangen
Germany	Universitätsklinikum Freiburg - Hospital	Freiburg
Germany	Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Hospital	Mainz-GE
Germany	Klinikum rechts der Isa der Technischen Universitaet Muenchen - Hospital	Munich
Netherlands	AMC	Amsterdam
Netherlands	Ziekenhuis Rijnstate - Hospital	Arnhem
Netherlands	Maastricht University Medical Center - Hospital	Maastricht
Norway	Alesund Hospital	Ålesund
Norway	Oslo University Hospital HF	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Calypso Biotech BV

Countries where clinical trial is conducted

Belgium,  Finland,  Germany,  Netherlands,  Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent adverse event		through study completion, an average of 3 months post last dose